BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Advanced solid tumors clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for advanced solid tumors: 1599 (518 sponsors; 133 newly posted in the last 180 days, 73 stopped in the last 180 days; 53 new-entrant sponsors). Momentum score 4.6, rank 89 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 14, Phase 1 536, Phase 2 430, Phase 3 4, Phase 4 0, N/A 16.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN20P2 14, P1 5, P3 111
Hutchmed HCM2P2 1, P3 100
Intra-IMMUSG Pte Ltd2P2 1, P3 101
SUNHO(China)BioPharmaceutical CO., Ltd.2P3 1, P2 100
Sichuan Baili Pharmaceutical Co., Ltd.26P1 20, P2 693
Bristol-Myers Squibb BMY12NA 1, P2 5, P1 601
Jiangsu HengRui Medicine Co., Ltd.12P2 8, P1 402
Merck Sharp & Dohme LLC MRK12P2 10, P1 241
Qilu Pharmaceutical Co., Ltd.12P2 7, P1 523
CSPC Megalith Biopharmaceutical Co.,Ltd.10P2 5, P1 4, NA 142
Hansoh BioMedical R&D Company10P1 8, P2 220
MediLink Therapeutics (Suzhou) Co., Ltd.10P2 7, P1 304
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY10P1 5, P2 503
BeOne Medicines ONC9P1 8, P2 121
Innovent Biologics (Suzhou) Co. Ltd.9P2 5, P1 421
LaNova Medicines Limited9P2 931
Shanghai Hengrui Pharmaceutical Co., Ltd.9P2 5, P1 400
Daiichi Sankyo8P1 4, P2 421
Eli Lilly and Company LLY8P1 7, P2 101
Boehringer Ingelheim7P1 6, P2 131
Exelixis EXEL7P1 703
GlaxoSmithKline7P2 3, P1 421
Novartis Pharmaceuticals NVS7P1 3, P2 3, NA 113
Pfizer PFE7P1 5, P2 211
Shanghai Henlius Biotech7P1 6, EARLY_P1 113

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P3EMD Serono Research & Development Institute, Inc.NCT03815643 Avelumab Program Rollover StudySolid Tumorsactive not recruiting205
2026-11-30 est.P1/P2Amgen AMGNNCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Advanced MTAP-null Solid Tumorsactive not recruiting329
2026-11-30 est.P1/P2Bio-Thera SolutionsNCT06341114 A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in PaAdvanced Solid Tumorsactive not recruiting112
2026-12 est.P1/P23D Medicines (Sichuan) Co., Ltd.NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsSolid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinomarecruiting170
2026-12 est.P1/P2Nanjing Leads Biolabs Co.,LtdNCT05170958 A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant TumorsAdvanced Solid Tumorrecruiting396
2026-12 est.P1/P2Rottapharm BiotechNCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersRefractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Caactive not recruiting107
2026-12 est.P1/P2AP Biosciences Inc.NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamrecruiting168
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P1/P2AkesoNCT05689853 Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsSolid Tumor, Adultrecruiting87
2026-12 est.P1/P2A2 Biotherapeutics Inc.NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionSolid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Smallactive not recruiting160
2026-12 est.P1/P2TiumBio Co., Ltd.NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsSolid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancerrecruiting140
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05785039 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System TumorsUrinary System Tumor; Solid Tumorrecruiting76
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05803018 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesGynecological Malignant Tumor; Solid Tumorrecruiting38
2026-12 est.P1/P2Guangzhou Gloria Biosciences Co., Ltd.NCT05909436 Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid TumorsSolid Tumorrecruiting107
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsUrothelial Carcinoma; Solid Tumorrecruiting52
2026-12 est.P1/P2Xenothera SASNCT06154291 FIH XON7 in Advanced/Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Cancerrecruiting255
2026-12 est.P1/P2Alyssum TherapeuticsNCT06234098 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, RefraSolid Tumorrecruiting100
2026-12 est.P1/P2Latticon Antibody Therapeutics, IncNCT06277219 A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)Advanced Solid Tumorrecruiting150
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P1/P2Georgiamune IncNCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsMelanoma Stage IV; Solid Tumorrecruiting117
2026-12 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06605222 A Trial of SHR-7787 Injection in Patients With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting201
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12 est.P2Ryvu Therapeutics SANCT06987058 RVU120 Rollover StudyAdvanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndromeenrolling by invitation14
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12 est.P1/P2Heron Neutron Medical Corp.NCT07691775 A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid TumorsSolid Tumorrecruiting30
2026-12-01 est.P2Intra-IMMUSG Pte LtdNCT04452955 A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid TumorsSolid Tumoractive not recruiting51
2026-12-01 est.P2EpicentRx, Inc.NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid TumorsSolid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcomaactive not recruiting140
2026-12-01 est.P1/P2FindCure Biosciences (ZhongShan) Co., Ltd.NCT06499350 A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid TumorsAdvanced Malignant Solid Tumorsrecruiting33
2026-12-01 est.P1/P2AP Biosciences Inc.NCT06669975 A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid TumorsAdvanced Solid Tumorrecruiting85
2026-12-05 est.P1/P2Suzhou Forlong Biotechnology Co., LtdNCT07131202 A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid TumorsAdvanced Solid Tumorsrecruiting130
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-24 est.P2Nanjing Leads Biolabs Co.,LtdNCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Advanced Solid Tumourrecruiting250
2026-12-30 est.P23D Medicines (Sichuan) Co., Ltd.NCT03667170 KN035 for dMMR/MSI-H Advanced Solid TumorsSolid Tumoractive not recruiting188
2026-12-30 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsSelected Subjects With Advanced Solid Tumorsactive not recruiting321
2026-12-30 est.P1/P2Suzhou Abogen Biosciences Co., Ltd.NCT06088004 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid TumorsSolid Tumor, Adultrecruiting218
2026-12-30 est.P1/P2L & L Bio Co., Ltd., Ningbo, ChinaNCT06468358 A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid TumorsSolid Tumorrecruiting194
2026-12-30 est.P3Jiangsu vcare pharmaceutical technology co., LTDNCT06658353 Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsLocally Advanced Solid Tumorrecruiting54
2026-12-31 est.P2Partner Therapeutics, Inc.NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Factive not recruiting250
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2026-12-31 est.P1/P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05265091 A Study of KL590586 in Patients With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting414
2026-12-31 est.P1/P2Impact Therapeutics, Inc. IBONCT05269316 Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid TumorsSolid Tumor; Advanced Solid Tumorrecruiting61
2026-12-31 est.P1/P2AskGene Pharma, Inc.NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.Advanced Solid Tumorsrecruiting594
2026-12-31 est.P1/P2Shanghai Pharmaceuticals Holding Co., LtdNCT05944224 A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.Advanced Solid Tumorsrecruiting63
2026-12-31 est.P2Allist Pharmaceuticals, Inc.NCT06008288 A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.KRAS P.G12C; Pancreatic Cancer; Solid Tumorrecruiting88
2026-12-31 est.P1/P2Shanghai Pharmaceuticals Holding Co., LtdNCT06214143 A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting68
2026-12-31 est.P1/P2Evopoint Biosciences Inc.NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsAdvanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancersrecruiting350
2026-12-31 est.P1/P2Jacobio Pharmaceuticals Co., Ltd.NCT06959615 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene AlterationAdvanced Solid Tumorrecruiting334
2026-12-31 est.P1/P2Shanghai Cell Therapy Group Co.,LtdNCT07146672 Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for TumorsSolid Tumor Cancerrecruiting12
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01 est.P1/P2LigaChem Biosciences, Inc.NCT05941507 A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsAdvanced Solid Tumorsrecruiting300
2027-01 est.P1/P2Jacobio Pharmaceuticals Co., Ltd.NCT06386146 JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C MutationSolid Tumorsrecruiting144
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsAdvanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancerrecruiting260
2027-01 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07298772 A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid TumorsAdvanced Solid Tumorrecruiting198
2027-01-16 est.P1/P2Corbus Pharmaceuticals Inc. CRBPNCT06265727 A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsSolid Tumor, Adultrecruiting348
2027-01-19 est.P1/P2Sanofi SNYNCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSolid Tumorrecruiting542
2027-01-23 est.P1/P2Egle TherapeuticsNCT06622486 First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid TumorsSolid Tumor, Adultrecruiting50
2027-01-25 est.P1/P2Novartis Pharmaceuticals NVSNCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lungactive not recruiting344
2027-01-29 est.P1/P2IDEAYA Biosciences IDYANCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumorsrecruiting336
2027-01-30 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06132217 A Study of Simmitinib Plus SG001 in Advanced Solid TumorsAdvanced Solid Tumornot yet recruiting168
2027-01-30 est.P1/P2Psivac LtdNCT06549946 Ixovex-1 Single Agent and Combination TherapySolid Tumor; Head and Neck Cancerrecruiting18
2027-01-31 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07202364 A Study of YL202 in Patients With Advanced Solid TumorsNon Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solidrecruiting100
2027-02 est.P1/P2Krystal Biotech, Inc. KRYSNCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsLung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancerecruiting250
2027-02 est.P1/P2DualityBio Inc.NCT06554795 First-in-human Study of DB-1419 for Advanced/Metastatic Solid TumorsSolid Tumor, Adultrecruiting360
2027-02 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT07136142 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsMalignant Solid Tumorrecruiting150
2027-02 est.P1/P2GI Innovation, Inc.NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNSrecruiting102
2027-02-01 est.P2Novartis Pharmaceuticals NVSNCT02934568 Ribociclib (LEE011) Rollover Study for Continued AccessContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Canactive not recruiting22
2027-02-10 est.P2AstraZeneca AZNNCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)active not recruiting127
2027-02-14 est.P1/P2Beijing BiotechNCT07589530 Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid TumorsAdvanced Solid Tumors; Metastatic Solid Tumors; TROP2-Expressing Solid Tumorsrecruiting60

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Unresectable Locally Advanced or Metastatic Solid Tumorsnot yet recruiting380
2026-11-13 est.P1/P2Regeneron Pharmaceuticals REGNNCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersAdvanced Solid Tumorsactive not recruiting548
2026-11-01 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05584800 Study of ZGGS18 in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting222
2026-11 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06737731 A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid TumorsMalignant Solid Tumorsrecruiting300
2026-11 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid TumorsNSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumorsrecruiting200
2026-11 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06015048 A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.HER2-expressing Advanced Solid Tumorsrecruiting364
2026-11 est.P1/P2Tyra Biosciences, Inc TYRANCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsLocally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcactive not recruiting310
2026-11 est.P1/P2Anbogen Therapeutics, Inc.NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC PatientsAdvanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutationsrecruiting61
2026-11 est.P2BeiGeneNCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsMSI-H/dMMR Solid Tumorsrecruiting200
2026-10-31 est.P1/P2LaNova Medicines LimitedNCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting392
2026-10-30 est.P1/P2Shanghai Henlius BiotechNCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsSolid Tumor Cancer; Non Small Cell Lung Cancerrecruiting105
2026-10-30 est.P1/P2Nouscom SRLNCT04041310 Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsSolid Tumor, Adultactive not recruiting115
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting444
2026-10 est.P1/P2Shanghai Shengdi Pharmaceutical Co., LtdNCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsSolid Tumorsrecruiting258
2026-10 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06057922 A Study YL201 in Patients With Selected Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting990
2026-10 est.P2Gilead Sciences GILDNCT05119907 Study of Sacituzumab Govitecan in Patients With Solid TumorSolid Tumoractive not recruiting53
2026-10 est.P1/P2Laminar PharmaceuticalsNCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid TumorsHigh-grade Glioma; Solid Tumor, Unspecified, Childrecruiting28
2026-10 est.P1/P2Immunocore Ltd IMCRNCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsSelect Advanced Solid Tumorsactive not recruiting410
2026-09-30 est.P1/P2Bristol-Myers Squibb BMYNCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting100
2026-09-30P2Incyte Corporation INCYNCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveAdvanced Solid Tumorterminated73
2026-09-30 est.P1/P2Turning Point Therapeutics, Inc. TPBNCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsLocally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumorsrecruiting75
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-09-22P1/P2Tango Therapeutics, Inc. TNGXNCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNon Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinomaactive not recruiting126
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-05 est.P1/P2Bristol-Myers Squibb BMYNCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting360
2026-09-01 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsAdvanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancerrecruiting414
2026-09-01 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05990452 Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting261
2026-09 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced SoSolid Tumornot yet recruiting240
2026-09 est.P1/P2Shanghai HyaMab Biotech Co.,Ltd.NCT05801237 PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid TumorLocally Advanced/Metastatic Solid Tumorsrecruiting120
2026-08-30 est.P1/P2Fujian Haixi Pharmaceuticals Co., Ltd.NCT06220318 Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsSolid Tumoractive not recruiting155
2026-08-01 est.P1/P2OncoResponse, Inc.NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsCancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanomrecruiting168
2026-08 est.P1/P2Jacobio Pharmaceuticals Co., Ltd.NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid TumorsSolid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Cerecruiting102
2026-08 est.P1/P2Treadwell Therapeutics, IncNCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerAdvanced Solid Tumor; Breast Canceractive not recruiting44
2026-08 est.P1/P2BicycleTx LimitedNCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionAdvanced Solid Tumoractive not recruiting200
2026-08 est.P1/P2Allist Pharmaceuticals, Inc.NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaNSCLC; Solid Tumoractive not recruiting315
2026-07-31 est.P1/P2NEC Bio B.VNCT06631079 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsSolid Tumoractive not recruiting20
2026-07-31 est.P2Hansoh BioMedical R&D CompanyNCT06112704 HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsAdvanced Solid Tumorrecruiting220
2026-07-30 est.P1/P2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05744427 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting725
2026-07-29P1/P2Incyte Corporation INCYNCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsSolid Tumors; Advanced Solid Tumors; Metastatic Solid Tumorsterminated9
2026-07-28 est.P1/P2Lantern Pharma Inc. LTRNNCT05933265 Study of LP-184 in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancactive not recruiting64
2026-07-22P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06233292 A Study of ZG005 in Patients With Advanced Solid TumorsSolid Tumorscompleted125
2026-07-01P1/P2Erasca, Inc. ERASNCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumorscompleted85
2026-07 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07102004 Study of MHB088C for Patients With Advanced Solid Malignant TumorsAdvanced/Metastatic Solid Tumorsrecruiting515
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-06-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT06974812 IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsUnresectable Locally Advanced or Metastatic Solid Tumorsrecruiting250
2026-06-30 est.P1/P2Multitude Therapeutics Inc.NCT06782334 AMT-116 in Patients with Solid TumorsAdvanced Solid Tumorsrecruiting144
2026-06-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid Tumornot yet recruiting360
2026-06-30 est.P1/P2LaNova Medicines LimitedNCT06187402 A Study of LM-24C5 For Advanced Solid TumorsAdvanced Solid Tumorrecruiting49
2026-06-30 est.P1/P2TiumBio Co., Ltd.NCT05204862 Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid TumorsAdvanced Solid Tumorrecruiting240
2026-06-30P1/P2Novita Pharmaceuticals, Inc.NCT05023486 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor MalignanciesAdvanced or Metastatic Solid Tumor Malignanciescompleted121
2026-06-30P1/P2Linnaeus Therapeutics, Inc.NCT04130516 Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabSolid Tumor, Adultactive not recruiting200
2026-06-22 est.P1/P2GlaxoSmithKlineNCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in ParticNeoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Canceractive not recruiting14
2026-06-22P1/P2Anaveon AGNCT06470763 A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)Advanced Solid Tumorcompleted63
2026-06-08P2Merck Sharp & Dohme LLC MRKNCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous ReSolid Tumorscompleted333
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06-02P1/P2Binhui Biopharmaceutical Co., Ltd.NCT04386967 OH2 Injection in Solid TumorsSolid Tumor; Melanomacompleted44
2026-06-01 est.P2Intra-IMMUSG Pte LtdNCT07541001 PRL3-Zumab in Patients With Advanced Solid TumorsAdvanced Malignant Solid Tumoractive not recruiting60
2026-06 est.P2AlaMab Therapeutics (Shanghai) Inc.NCT06416358 A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have FailedAdvanced Solid Tumors With Bone Only Metastasisnot yet recruiting144
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-06 est.P1/P21ST Biotherapeutics, Inc.NCT05761223 A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849Advanced Solid Tumorrecruiting151
2026-05-29P1/P2Amgen AMGNNCT03600883 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodKRAS p.G12C Mutant Advanced Solid Tumorscompleted713

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "advanced solid tumors"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.